Wirkstoffe & Arzneimittelsicherheit

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (51)

Wechselwirkungen · Constella

Constella 290 micrograms hard capsules · Abschnitt 4.5 · PDF-Seite 3

HOS-215720 · Präparat HOS-155512

In cases of severe or prolonged diarrhoea, absorption of other oral medicinal products may be affected. The efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception (see the prescribing information of the oral contraceptive). Caution should be exercised when prescribing medicinal products absorbed in the intestinal tract with a narrow therapeutic index such as levothyroxine as their efficacy may be reduced.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-25T17:28:00Z · SHA-256 1b8acfd844e9f1cdcf705e8a60fee70d0baef38df36c3dc76756a130a5ec50d8 · Passage d4e002663704843c11442e9d444c1c184fed740df47ff481839c35b6e66b806f · Zeichen 1000–1515 im Abschnitt

Wechselwirkungen · Nexium Control

Nexium Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-127710 · Präparat HOS-096457

Medicinal products with pH dependent absorption Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. The absorption of medicinal products taken orally such as ketoconazole, itraconazole, erlotinib and levothyroxine can decrease and dose adjustments may be required during treatment with esomeprazole and the absorption of digoxin can increase during treatment with esomeprazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) digoxin (HOS-086172) itraconazole (HOS-084516) erlotinib (HOS-113527) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-10-13T14:26:00Z · SHA-256 d4554b4b11397de3effc8bd7e120a7d0370b488e26268f079cad37ef37aaaf22 · Passage 74b963434e08d1964dfc9e0661b70fe32e3d04c1352196df1f59537df4df12b7 · Zeichen 3058–3562 im Abschnitt

Wechselwirkungen · Nexium Control

Nexium Control 20 mg gastro-resistant hard capsules · Abschnitt 4.5 · PDF-Seite 18

HOS-127761 · Präparat HOS-096457

Medicinal products with pH dependent absorption Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. The absorption of medicinal products taken orally such as ketoconazole, itraconazole, erlotinib and levothyroxine can decrease and dose adjustments may be required during treatment with esomeprazole and the absorption of digoxin can increase during treatment with esomeprazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) digoxin (HOS-086172) itraconazole (HOS-084516) erlotinib (HOS-113527) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Xtandi

Xtandi - 40 mg soft capsules · Abschnitt 4.5 · PDF-Seite 6

HOS-127857 · Präparat HOS-096479

• Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) indinavir (HOS-084518) diltiazem (HOS-086288) prednisolone (HOS-086337) nifedipine (HOS-086289) nicardipine (HOS-090619) valproic acid (HOS-088515) atorvastatin (HOS-086304) felodipine (HOS-108908) carbamazepine (HOS-085618) simvastatin (HOS-086158) digoxin (HOS-086172) diazepam (HOS-085904) calcium (HOS-085615) clonazepam (HOS-116372) zolpidem (HOS-086327) dexamethasone (HOS-084535) bisoprolol (HOS-127867) clopidogrel (HOS-087927) clarithromycin (HOS-084517) tacrolimus (HOS-085202) cabazitaxel (HOS-124028) fentanyl (HOS-086196) haloperidol (HOS-085602) ritonavir (HOS-084521) propranolol (HOS-084529) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) midazolam (HOS-086167) primidone (HOS-090551) omeprazole (HOS-085912) tramadol (HOS-112871) verapamil (HOS-090602) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3973–4850 im Abschnitt

Wechselwirkungen · Xtandi

Xtandi - 40 mg film-coated tablets Xtandi - 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 36

HOS-127925 · Präparat HOS-096479

• Analgesics (e.g. fentanyl, tramadol) • Antibiotics (e.g. clarithromycin, doxycycline) • Anticancer agents (e.g. cabazitaxel) • Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid) • Antipsychotics (e.g. haloperidol) • Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel) • Betablockers (e.g. bisoprolol, propranolol) • Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil) • Cardiac glycosides (e.g. digoxin) • Corticosteroids (e.g. dexamethasone, prednisolone) • HIV antivirals (e.g. indinavir, ritonavir) • Hypnotics (e.g. diazepam, midazolam, zolpidem) • Immunosuppressant (e.g. tacrolimus) • Proton pump inhibitor (e.g. omeprazole) • Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin) • Thyroid agents (e.g. levothyroxine)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Velphoro

Velphoro 500 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 4

HOS-128598 · Präparat HOS-096593

Velphoro is almost not absorbed from the gastrointestinal tract. Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow therapeutic window, the clinical effect and adverse events should be monitored, on initiation or dose- adjustment of either Velphoro or the concomitant medicinal product, or the physician should consider measuring blood levels. When administering any medicinal product that is already known to interact with iron (like alendronate and doxycycline) or has the potential to interact with sucroferric oxyhydroxide based only on in vitro studies like levothyroxine, the medicinal product should be administered at least one hour before or two hours after Velphoro.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) iron (HOS-085656) alendronate (HOS-114516) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T02:00:00Z · SHA-256 1e5416d301655970abd63bd7dd9bc2b3e6c52e5764330496810361230bfa8aa9 · Passage d7272cae22df8b70da7d3b6c14d39dc9ddeb72ec777dd381e6dfef7c18a47c19 · Zeichen 0–764 im Abschnitt

Wechselwirkungen · Velphoro

Velphoro 125 mg oral powder in sachet · Abschnitt 4.5 · PDF-Seite 14

HOS-128628 · Präparat HOS-096593

Velphoro is almost not absorbed from the gastrointestinal tract. Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow therapeutic window, the clinical effect and adverse events should be monitored, on initiation or dose- adjustment of either Velphoro or the concomitant medicinal product, or the physician should consider measuring blood levels. When administering any medicinal product that is already known to interact with iron (like alendronate and doxycycline) or has the potential to interact with sucroferric oxyhydroxide based only on in vitro studies like levothyroxine, the medicinal product should be administered at least one hour before or two hours after Velphoro.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxycycline (HOS-127860) iron (HOS-085656) alendronate (HOS-114516) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Feraccru

Feraccru 30 mg hard capsules · Abschnitt 4.5 · PDF-Seite 3–4

HOS-128833 · Präparat HOS-096637

Oral iron is known to reduce the absorption of penicillamine, bisphosphonates, ciprofloxacin, entacapone, levodopa, levofloxacin, levothyroxine (thyroxine) moxifloxacin, mycophenolate, 3 norfloxacin and ofloxacin. These medicinal products should be given at least 2 hours apart from Feraccru.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norfloxacin (HOS-085181) penicillamine (HOS-086112) ciprofloxacin (HOS-085177) levofloxacin (HOS-128837) iron (HOS-085656) moxifloxacin (HOS-085604) mycophenolate (HOS-085189) levodopa (HOS-086559) entacapone (HOS-087873) ofloxacin (HOS-128840) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-06-25T15:59:00Z · SHA-256 b2d699d0ce35a74de8558e02a2453b5b268ff8751bf546e8905e41445f10e069 · Passage 2085def681973501f31049740957af47ac3047c00ac4faae7f7f216f62160e30 · Zeichen 860–1204 im Abschnitt

Wechselwirkungen · Lokelma

Lokelma 5 g powder for oral suspension Lokelma 10 g powder for oral suspension · Abschnitt 4.5 · PDF-Seite 4

HOS-133779 · Präparat HOS-097504

As sodium zirconium cyclosilicate is not absorbed or metabolised by the body, and does not meaningfully bind other medicinal products, there are limited effects on other medicinal products. Sodium zirconium cyclosilicate can transiently increase gastric pH by absorbing hydrogen ions and can lead to changes in solubility and absorption kinetics for co-administered medicinal products with pH-dependent bioavailability. In a clinical drug-drug interaction study conducted in healthy subjects co-administration of sodium zirconium cyclosilicate with amlodipine, clopidogrel, atorvastatin, furosemide, glipizide, warfarin, losartan or levothyroxine did not result in clinically meaningful drug- drug interactions. Consistent with co-administration of dabigatran with other gastric acid modifiers, dabigatran Cmax and AUC values were approximately 40% lower when co-administered with sodium zirconium cyclosilicate. No dose adjustments or separation of time of dosing are required for any of these medicinal products. However, sodium zirconium cyclosilicate should be administered at least 2 hours before or 2 hours after oral medicinal products with clinically meaningful gastric pH dependent bioavailability.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): furosemide (HOS-089060) glipizide (HOS-109460) hydrogen (HOS-133780) losartan (HOS-087482) sodium (HOS-109681) zirconium (HOS-133790) atorvastatin (HOS-086304) amlodipine (HOS-086287) dabigatran (HOS-112096) lead (HOS-085592) clopidogrel (HOS-087927) warfarin (HOS-085950) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-02T16:15:00Z · SHA-256 9a57e63114421578bcab7ac6769b720be4b42c5e469c19bbe95a69fe93e5ab56 · Passage beb6ab5fe4577bd3e865808e3b07eb14b511be736d3bd2254e5fd8d62121763c · Zeichen 340–1547 im Abschnitt

Wechselwirkungen · Erleada

Erleada 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-139366 · Präparat HOS-098330

Induction of CYP3A4 by apalutamide suggests that UDP-glucuronosyl transferase (UGT) may also be induced via activation of the nuclear pregnane X receptor (PXR). Concomitant administration of Erleada with medicinal products that are substrates of UGT (e.g., levothyroxine, valproic acid) can result in lower exposure to these medicinal products. When substrates of UGT are co-administered with Erleada, evaluation for loss of efficacy of the substrate should be performed and dose adjustment of the substrate may be required to maintain optimal plasma concentrations.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valproic acid (HOS-088515) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-22T12:55:00Z · SHA-256 0e855910bdce0fdee217ba5d06d9b56e25e15ba99cd5eb9f6069185d820c69fe · Passage 69948dd3ccdc4320113bb13386b6cbb467a736047d3dccaed7236621eb7ffb60 · Zeichen 5051–5617 im Abschnitt

Wechselwirkungen · Erleada

Erleada 240 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 26

HOS-139416 · Präparat HOS-098330

Induction of CYP3A4 by apalutamide suggests that UDP-glucuronosyl transferase (UGT) may also be induced via activation of the nuclear pregnane X receptor (PXR). Concomitant administration of Erleada with medicinal products that are substrates of UGT (e.g., levothyroxine, valproic acid) can result in lower exposure to these medicinal products. When substrates of UGT are co-administered with Erleada, evaluation for loss of efficacy of the substrate should be performed and dose adjustment of the substrate may be required to maintain optimal plasma concentrations.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valproic acid (HOS-088515) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Rybelsus

Rybelsus 1.5 mg tablets Rybelsus 4 mg tablets Rybelsus 9 mg tablets Rybelsus 25 mg tablets Rybelsus 50 mg tablets · Abschnitt 4.5 · PDF-Seite 6

HOS-143113 · Präparat HOS-098932

Thyroxine Total exposure (Area Under the Curve (AUC)) of thyroxine (adjusted for endogenous levels) was increased by 33% following administration of a single dose of levothyroxine. Maximum exposure (Cmax) was unchanged. Monitoring of thyroid parameters should be considered when treating patients with semaglutide at the same time as levothyroxine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-22T10:41:00Z · SHA-256 92f8cd4bbfc5e1b56bb6383ebaaeb7f5b41beee2ff07448d020f2af2ee2b7172 · Passage 14bf5ecb6e5657ba3be4dce22567ce5c2e79a934c8778195def184930795d244 · Zeichen 158–506 im Abschnitt

Wechselwirkungen · Rybelsus

Rybelsus 3 mg tablets Rybelsus 7 mg tablets Rybelsus 14 mg tablets Rybelsus 25 mg tablets Rybelsus 50 mg tablets · Abschnitt 4.5 · PDF-Seite 30

HOS-143153 · Präparat HOS-098932

Thyroxine Total exposure (Area Under the Curve (AUC)) of thyroxine (adjusted for endogenous levels) was increased by 33% following administration of a single dose of levothyroxine. Maximum exposure (Cmax) was unchanged. Monitoring of thyroid parameters should be considered when treating patients with semaglutide at the same time as levothyroxine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Emcitate

Emcitate 350 microgram dispersible tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-145404 · Präparat HOS-099344

Other medicinal products used to treat thyroid conditions Taking tiratricol in combination with other thyromimetic medicinal products or other medicinal products used to treat thyroid conditions (e.g. levothyroxine, propylthiouracil, and carbimazole) may increase the risk of symptoms of hyperthyroidism or hypothyroidism.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propylthiouracil (HOS-145405) carbimazole (HOS-145406) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-03-11T10:55:11Z · SHA-256 f1406017bf71ca6ed21c19c56ad9b2f42db03a6c0c95a8b1a995b810587719f2 · Passage 24ca6b59ae9e5b38f62975639e9d5e0e3c78da9ae0abe357c36071477d57cbf2 · Zeichen 4300–4622 im Abschnitt

Wechselwirkungen · Retsevmo

Retsevmo 40 mg hard capsules Retsevmo 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10

HOS-146843 · Präparat HOS-099572

Selpercatinib could inhibit D2 deiodinase and thereby decrease the conversion of levothyroxine (T4) to triiodothyronine (T3). Patients could therefore have an insufficient response to substitution with levothyroxine and supplementation with liothyronine may be needed (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): liothyronine (HOS-146845) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-03T11:29:00Z · SHA-256 ea39918a3fb80726ed18974b1aa44d085db9e48e01020d5741da30903ff4eadc · Passage a417720091fb5ec15ccace063e22b21d361bb2e0edd6b5cf89263db3ba56753f · Zeichen 4444–4730 im Abschnitt

Wechselwirkungen · Retsevmo

Retsevmo 40 mg film-coated tablets Retsevmo 80 mg film-coated tablets Retsevmo 120 mg film-coated tablets Retsevmo 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 44

HOS-146896 · Präparat HOS-099572

Selpercatinib could inhibit D2 deiodinase and thereby decrease the conversion of levothyroxine (T4) to triiodothyronine (T3). Patients could therefore have an insufficient response to substitution with levothyroxine and supplementation with liothyronine may be needed (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): liothyronine (HOS-146845) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Wegovy

Wegovy 1.5 mg tablets Wegovy 4 mg tablets Wegovy 9 mg tablets Wegovy 25 mg tablets · Abschnitt 4.5 · PDF-Seite 44

HOS-147341 · Präparat HOS-099634

Thyroxine Total exposure (Area Under the Curve (AUC)) of thyroxine (adjusted for endogenous levels) was increased by 33% following administration of a single dose of levothyroxine. Maximum exposure (Cmax) was unchanged. Monitoring of thyroid parameters should be considered when treating patients with semaglutide at the same time as levothyroxine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-21T13:06:00Z · SHA-256 d18d21c1225b1515e1fb09608f43194fc51f46bec34dce897074f105b8785b7d · Passage 14bf5ecb6e5657ba3be4dce22567ce5c2e79a934c8778195def184930795d244 · Zeichen 158–506 im Abschnitt

Wechselwirkungen · Wezenla

WEZENLA 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7

HOS-151578 · Präparat HOS-100575

In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was explored. There were no indications of an interaction with these concomitantly administered medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the studied population) were treated concomitantly with these medicinal products for at least 90% of the study period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in patients with ulcerative colitis.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 1160a00c4608f29067bc36e867879ffd80cb08b3f41e1bf69a2923a3206527c8 · Zeichen 498–1526 im Abschnitt

Wechselwirkungen · Wezenla

WEZENLA 45 mg solution for injection WEZENLA 45 mg solution for injection in pre-filled syringe WEZENLA 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 28

HOS-151625 · Präparat HOS-100575

In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was explored. There were no indications of an interaction with these concomitantly administered medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the studied population) were treated concomitantly with these medicinal products for at least 90% of the study period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in patients with ulcerative colitis.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Wechselwirkungen · Wezenla

WEZENLA 45 mg solution for injection in pre-filled pen WEZENLA 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 55

HOS-151658 · Präparat HOS-100575

In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen, acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was explored. There were no indications of an interaction with these concomitantly administered medicinal products. The basis for this analysis was that at least 100 patients (> 5% of the studied population) were treated concomitantly with these medicinal products for at least 90% of the study period. The pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 509d6d92dbc48f1b359d8b9cd57701ef0c13ee00b8d9b7ec2dd79e7280071ea4 · Zeichen 498–1393 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.